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Risk Prediction in Cardiovascular Medicine
Integrating Information From Novel Risk Factors With
Calculated Risks
The Critical Impact of Risk Factor Prevalence
Albertus J. Kooter, MD; Piet J. Kostense, PhD; Jan Groenewold, PhD; Abel Thijs, MD;
Naveed Sattar, MD; Yvo M. Smulders, MD
Case vignette: a 60-year-old man visits his physician forassessment of his 10-year cardiovascular risk. On the
basis of his systolic blood pressure, lipid profile, smoking
status, and the fact that he is nondiabetic, the Framingham
risk score estimates his risk to be 8%. The physician wonders
if he could further specify the patients risk by performing an
additional test like coronary calcium score or microalbumin-
uria (MA). For matters of convenience and costs he decides to
test MA, which turns out positive. Assuming that MA has an
invariable and exact relative risk (RR), independent from the
aforementioned classical risk factors, of 2.0, what would this
man’s estimated risk become?
The Problem
Prediction of absolute disease risk is an essential component
of cost-effective disease prevention strategies. In cardiovas-
cular disease (CVD) prevention, for example, antiplatelet and
statin therapy is applied if absolute risk of CVD is considered
sufficiently high. Various prediction models are available for
the purpose of risk calculation. These models are derived
from large population-based cohorts in which conventional
CVD risk factors and prospective event registrations are
available. Well known examples include the Framingham risk
score and the risk model of the European SCORE
consortium.1,2
Obviously, with regard to individual risk estimation, risk
models have inherent shortcomings in terms of precision and
reliability. In an attempt to improve risk prediction, much
focus has been on the potential benefit of adding information
relating to novel risk factors. Various statistical methods have
been developed to assess the ability of novel risk factors to
improve risk stratification. These methods include assessment
of discrimination and calibration of the conventional versus
the updated risk model.3,4 The ultimate goal of adding novel
risk factors is to improve a patient’s health by correctly
reclassifying him or her into high, intermediate, and low risk
categories for which the net reclassification improvement is
one appropriate parameter.5,6
Although models may, as judged from the net reclassifi-
cation improvement, improve as a result of including a novel
risk factor, such expanded models are hardly used in clinical
practice. Moreover, literature addressing novel risk factors
often does not provide these expanded risk models but,
instead, provides an independent RR or standardized  of the
novel risk factor.
Integrating a novel risk factor in a new model is very
different from using a novel risk factor on top of an existing
model. In the latter context, the model delivers a baseline risk
and the independent RR from the novel risk factor must
somehow be used to convert this baseline risk into a recal-
culated risk. Although several national and international
guidelines encourage the use of novel risk factors, they do not
describe how to obtain a new recalculated risk using this
additional information. Intuitively, and sometimes explicitly,
the RR of novel risk factor is directly translated into a
multiplication factor.7,8 In other words, the risk of the patient
in the case vignette would be multiplied by 2.0 to give a
recalculated risk of 16%, assuming that the RR of 2 implies
doubling of risk. We will explain that this reasoning is
incorrect.
Imagine the RR and the multiplication factor to be identi-
cal. In the example of the case vignette, if the multiplication
factor would be either 2.0 (MA present) or 1.0 (MA absent),
the recalculated risk can only remain unchanged or adjusted
upward but never downward. Hence, in the stratum (ie, the
imaginary group of individuals with the same Framingham
risk factor profile), the average risk would increase, solely by
adding risk information. This cannot be correct because
adding risk information simply cannot increase average risk.
Hence, upward adjustments of risk due to presence of an
additional risk factor in some individuals should be compen-
sated by downward adjustments for absence of the same risk
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factor in other individuals, eventually generating a stable risk
for each risk stratum. Literature on high-sensitivity C-reactive
protein (hsCRP), for example, explains that hsCRP has the
ability to reclassify upward as well as downward.9 Although
this may seem obvious, many guidelines describe novel
(emerging) risk factors as principally being helpful to place
patients from intermediate- into high-risk categories.10–12
It follows that the RR of the novel risk factor and the
multiplication factor for baseline risk cannot be considered
synonymous. So how can we translate the RR into a multi-
plication factor. In the case vignette, if the RR is indeed 2.0,
how does the patients risk change in case of presence or
absence of MA?
Below, we will focus on the principles and mathematics
when the novel risk factor is a dichotomous (like the one
presented in the case vignette), ordinal, or continuous risk
factor. The conclusion is sobering: Even perfect knowledge
of the exact and truly independent RR of a novel risk factor
is insufficient without a reliable estimate of its prevalence.
We explain this in the context of CVD risk stratification, but
the principles outlined apply to risk prediction in every
clinical context, in risk models as well as predictions based on
clinical experience.
The Solution for a Dichotomous Risk Factor
In the example given, the additional risk information con-
sisted of a dichotomous variable with a RR of 2.0.13 An
intuitive response might be that the presence of MA would
increase the risk by a factor 2.0, so from 8% to 16%. We will
explain why this is incorrect.
Firstly, consider that the risk of 8% for this individual is in
fact an estimate for a mix of persons that, together, make up
the stratum of people with the same profile of conventional
(Framingham) risk factors. Some in this stratum will have had
MA and some will not. Therefore, the 8% should be regarded
as a weighted mean of the risks for those with and those
without MA.
Imagine now, for the sake of argument, that over 99% of
persons in the original 8%-risk stratum would have had MA.
Then, the risk of the patient in the example would not
increase by any significant margin by having MA (multipli-
cation factor 1.0). After all, the person was already ex-
pected to have MA, so having MA does not change risk
appreciably. However, in the exceptional case of a patient
with this risk profile not having MA, his risk would be
substantially lower than 8%. As the defined RR is 2.0, his risk
should thus be 4% (multiplication factor 0.5). Since he is
a rare individual in this stratum, the baseline average risk
remains unaffected.
Conversely, if 1% of individuals in the stratum would
have had MA, not having MA would not change the patient’s
risk by any considerable margin (multiplication factor 1.0).
Having MA, on the other hand, although a rare event,
increases his risk by almost the full multiplication factor of
2.0, thus reaching 16%. Again, the baseline risk will be 8%
because this individual with MA is a rare one.
It follows that the RR of 2.0 translates into varying
multiplication factors and, as demonstrated above, the crucial
determinant of the variation of the multiplication factor is its
prevalence. Depending on the prevalence of MA in the
stratum in which a patient fits, presence of MA translates into
a multiplication factor of between 1.0 (if prevalence of MA is
near 100%) and 2.0 (if prevalence of MA approaches 0%).
Conversely, the absence of MA translates into a multiplica-
tion factor of between 0.5 (if prevalence is near 100%) and
1.0 (if prevalence is near 0%).
In less extreme examples of prevalence, the multiplication
factors vary within the margins indicated, and what is
required now to convert RRs into multiplication factors for
baseline risk is calculation of the weighted mean RR.
For example, if the prevalence of MA in the original
8%-risk stratum of the example is 60%, the risks for those
with and without MA would be 10% and 5%, respectively
(Formula 1, further explained in online-only Data Supple-
ment). This can be understood as follows: The difference in
risk between the groups with and without MA always
corresponds to the RR of 2.0 for MA which, after all, was
considered to be precise and reliable across all risk strata. The
original 8% thus must be a weighted mean of those with and
those without MA and the risks differing by a factor of 2.0.
From these components, risks for those with and without MA
can be calculated as 10% and 5%, respectively, and indeed,
0.610%0.45%8%.
Formula 1
rp  RR(1p)
MF()RR/r
R()Rbl  MF()
R()R()/RR
where rweighted mean RR; pprevalence of novel risk
factor; RRrelative risk of the novel risk factor;
MF()multiplication factor for Rbl to obtain R();
R()recalculated risk in presence of novel risk factor;
Rblbaseline risk; and R()recalculated risk in absence of
novel risk factor.
A graphic representation of how the recalculated risk (after
applying the novel risk factor) depends on both RR and
prevalence of MA is shown in Figure 1. A generic Figure (for
Figure 1. Association between the prevalence of MA and recal-
culated risk. The recalculated risk is presented for a patient as
in the case vignette: a baseline risk of 0.08 (8%), and a novel
risk factor (ie, MA) with a consistent RR of 2.0. MA indicates
microalbuminuria.
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any dichotomous novel risk factor) is presented in the
online-only Data Supplement.
The Solution for Ordinal Risk Factors
Some novel risk factors are separated in 	2 categories, for
example hsCRP.14 Imagine that the physician in the example
case would have opted for measurement of hsCRP instead of
MA to recalculate risk. High-sensitivity C-reactive protein is
commonly divided into 3 categories: hsCRP 1 mg/L, 1 to 3
mg/L and 	3 mg/L. Suppose now that, in the risk stratum to
which the patient is allocated on the basis of the conventional
risk-factor profile, the (hypothetical) prevalences of these 3
categories are 0.1, 0.4, and 0.5, with corresponding RRs of
1.0, 1.25, and 2.0.
As is the case for dichotomous risk factors, the first step
is to define a weighted mean RR for the entire stratum,
which is determined by the RRs of the categories as well as
their prevalences. The weighted mean RR for the example
presented0.110.41.250.521.6.
We now compare the RR of the patient to this weighted
mean RR. Our patient’s hsCRP is 2.2 mg/L, corresponding to
a RR of 1.25. His baseline risk was 8%. The recalculated risk
will be (1.25/1.6)8%6.3%. Thus, although having an
added risk factor with a RR higher than 1.0 (ie, 1.25), his risk
is adjusted downward because most patients in his stratum
have the higher RR of 2.0.
The mathematical relationship between recalculated risk
and prevalence of an ordinal novel risk factor for any level of
RR and prevalence (P) is shown in Formula 2 (further
explained in the online-only Data Supplement).
Formula 2
rp1  RR1p2  RR2 ……. pn  RRn
MFxRRx/r
RxRbl*MFx
where rweighted mean RR; p1prevalence of lowest
level of risk; pnprevalence of highest level of risk;
RR1relative risk of lowest level of risk (1); RRnrelative
risk of highest level of risk; xxth level of risk; Rblbaseline
risk; MFxmultiplication factor for patient with RRx; RRx
relative risk of xth level of risk; and Rxrecalculated risk for
patient with RRx.
Figure 2 shows the recalculation of risk by means of the
weighted mean RR for 3 different levels of hsCRP with their
accompanying RR. A generic Figure (for any ordinal novel
risk factor) is presented in the online-only Data Supplement.
The Solution for Continuous Risk Factors
Suppose the physician in the case vignette would have
ordered a homocysteine (hcy) measurement. Homocysteine is
commonly considered as a continuous risk factor for CVD.15
Compared with dichotomous and ordinal risk factors, recal-
culation is much more complicated for a continuous risk
factor. Usually, the relationship between the continuous risk
factor and risk is multiplicative (ie, risk increases by a factor).
This multiplicative association precludes simple recalculation
of baseline risk. A more thorough description of this problem
is presented in the online-only Data Supplement.
Instead, we propose a pragmatic approach, which is to
convert the continuous risk factor to risk categories. One
could dichotomize the risk factor in low or high value or
trichotomize, as in in the example of hsCRP, or make more
categories, such as in the example of the coronary calcium
score.14,16 The recalculation of risk then follows the same
pattern as outlined above for dichotomous and ordinal risk
factors.
Discussion
We have shown that using additional risk information on top
of information in a traditional risk model requires much more
than a precise estimate of the independent RR of the novel
risk factor. In fact, knowledge of the RR is insufficient
without knowing the prevalence of the novel risk factor.
The importance of the distribution of novel risk factors has
been reported previously.16 We have followed up on this by
offering a generic and quantitative solution for translating
RRs into multiplication factors for baseline risk.
Recently, the American Heart Association listed recom-
mendations for reporting of novel risk markers.17 These
recommendations involved reporting the (independent) RR of
the new marker and its statistical significance, accuracy, and
discrimination properties. If the novel risk factor is to be used
within a new model, these recommendations suffice. How-
ever, if the novel risk factor is to be used on top of an existing
model, which the American Heart Association recommenda-
tions consider appropriate in some situations, knowledge of
its prevalence becomes pivotal. However, reporting the prev-
alence of novel risk markers was not included in the Amer-
ican Heart Association recommendations. We have shown
that the impact of prevalence is large, and without knowledge
of prevalence recalculation of risk is impossible.
Recalculating using prevalence data involves 2 assump-
tions that merit discussion. First, we need to know the
prevalence of the novel risk factor in the original cohort
because this is the cohort we refer to if we estimate baseline
risk. It may be possible that the novel risk factor, like MA,
has been measured in the original cohort and these data are
available. It is more likely, as is true for more laborious and
Figure 2. Association between weighted mean RR and recalcu-
lated risk for 3 levels (ordinals) of hsCRP. RR indicates relative
risk; weighted mean RR indicates a weighted RR of the whole
stratum, weighted by prevalence and RR of each of the 3 levels
(ordinals) of hsCRP; hsCRP, high-selective C-reactive protein.
Baseline risk0.08 (8%).
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expensive markers (eg, coronary calcium score), that the
novel risk factor was not measured in the original cohort. If
this is the case, we could project the prevalence of the novel
risk factor in a different cohort onto the original cohort. We
would then assume the original cohort (eg, Framingham) to
be comparable in all respects to the alternative cohort (eg, the
subjects for whom the RR of the novel risk factor has been
obtained). Any difference in confounder adjustments or
differences in other characteristics could make this projection
somewhat inaccurate.
Second, even if the overall prevalence of the novel risk
factor in the original cohort is known, it is not precise enough
because prevalence presumably will differ across different
strata within the cohort. Commonly, prevalence increases
when risk is higher because risk factors are often correlated,
and with increasing risks the prevalence of the novel risk
factor is also likely to increase. Therefore, it is of utmost
importance to know the prevalence in each risk stratum (ie,
in patients with risk profiles that are comparable to those of
patients for whom risk will be re-estimated). A diabetic
patient, for example, who smokes and has high blood pres-
sure is more likely to have MA compared with one having
none of these risk factors. For our patient, in the stratum with
a risk of 8%, knowledge of the prevalence of MA in the
whole Framingham cohort would not be sufficiently precise.
In fact, we would have to know its prevalence within this
stratum.
If distribution of the novel risk factor is not known, one
could estimate it by means of regression analysis using
classical risk factors as independent predictors and novel risk
factor as outcome. This has been done in some instances, like
for hsCRP and coronary calcium score, but is certainly not
commonly practiced, causing significant lack of clarity on
risk-factor distributions in the literature.16,18
Notwithstanding these shortcomings, and even in the absence
of information on prevalence, understanding the impact of
prevalence is important. Indeed, assuming the novel risk factor
to be correlated with other risk factors, one should realize that
a higher risk accompanies a higher prevalence of the novel
risk factor. The higher the prevalence of the novel risk
factor, the less the likelihood that presence of the novel
risk factor substantially reclassifies upward. Consequently,
absence of the novel risk factor reclassifies downward
more substantially.
Conversely, in subjects at low risk (and thus an anticipated
low prevalence of the novel risk factor) presence of the novel
risk factor reclassifies more substantially than its absence.
This is close to intuition, which tells us that the expected is
less likely to be informative than the unexpected.
Correct recalculation of risk therefore depends on several
assumptions that are difficult to meet in practice. Still,
guidelines on cardiovascular risk explicitly encourage the use
of specific novel risk factors to improve risk stratification but
do not explain how to use this extra information. Usually,
novel risk factors are used to place patients in higher
categories of risk. The National Cholesterol Education Pro-
gram–Adult Treatment Panel III (NCEP-ATPIII) guideline,
for example, states that for some patients “emerging risk
factors might be integrated into ATP III risk assessment … to
elevate persons …. to the category of CHD risk equivalent.”10
The Seventh Report of the Joint National Committee on the
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC VII) guideline states that “albuminuria
is associated with increased cardiovascular risk,” and the US
Preventive Services Task Force considers a novel risk factor
as clinically useful and “when assessed in intermediate-risk
persons, it should reclassify a substantial portion of them as
high-risk.”11,12 However, as we have clearly illustrated, up-
ward reclassification is just 1 side of the coin. If added risk
information is introduced, upward and downward reclassifi-
cation in the entire stratum must balance out.
In summary, guidelines stimulate the use of novel risk
factors above the well-known risk factors that make up
existing risk models. How to use the novel risk factor is less
well explained, with disproportionate emphasis on upward
reclassification. We show that if a novel risk factor is used to
recalculate risk, detailed knowledge of the prevalence of this
risk factor, specific to the patients profile, is essential.
Disclosures
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SUPPLEMENTAL MATERIAL 
 
Formula 1 provides the mathematical relationships between recalculated risk and prevalence 
of a dichotomous novel risk factor for any level of relative risk (RR) and prevalence (P). 
 
 Formula 1 
[r]  = p*RR + (1-p)  
MF(+)  = RR/[r] 
R(+)  = Rbl*MF(+)  
 R(-)  =  R(+)/RR 
  
[r] = weighted mean relative risk; p= prevalence of novel risk factor; RR=relative risk of the 
novel risk factor; MF(+) = multiplication factor for Rbl to obtain R(+); R(+)= recalculated risk in 
presence of novel risk factor; Rbl = baseline risk; R(-)= recalculated risk in absence of novel risk 
factor  
 
Derivation of formula 1 for a dichotomous risk factor 
Imagine a stratum with a baseline risk on a certain outcome. The subjects in this risk stratum can be 
divided into those with and those without the novel risk factor. The relative risk (RR) of the novel risk 
factor applies to those subjects who have the novel risk factor. In absence of the novel risk factor, 
RR=1.  
Baseline risk of the stratum is the sum of risks of both groups, each contributing with their specific 
weight. This weight is determined by the product of the prevalence (p) of this risk factor and its 
accompanying RR. In the presence of the novel risk factor, this weight = p*RR. In absence of this risk 
factor, it will be (1-p)*1 = 1-p. 
The sum of both weights is  p*RR + (1-p) and can be considered as a weighted mean of relative risks. 
This ‘weighted mean RR’ = [r] 
 
The next step is to compare the RR of the novel risk factor to this ‘weighted mean RR’. This will give 
us a multiplication factor (in presence of novel risk factor) for baseline risk. 
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MF(+) =  RR/[r]   
Finally, to obtain recalculated risk, we must multiply baseline risk with this multiplication factor, so: 
recalculated risk for patient with the novel risk factor = Rbl*MF(+) = R(+) 
In absence of the novel risk factor, recalculated risk R(-) will be R(+)/RR since the ratio between patients 
with and without the novel risk factor is the RR. 
 
For example, if baseline risk is 8%, the prevalence of the risk factor is 0.6, and the risk factor has an 
independent relative risk of 2, then  
[r]  = 0.6*2 + (1-0.6) = 1.6 
MF(+)  = 2/1.6 = 1.25 
R(+) = 0.08*1.25 = 0.1 = 10%  
R(-)  = 0.1/2 = 0.05 = 5%.  
 
A graphic representation of how the multiplication factor depends on both relative risk and prevalence 
of a dichotomous novel risk factor is shown in figure 1a. 
 
0 0.2 0.4 0.6 0.8 1.0
novel risk
factor absent
novel risk
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0
1/RR
1
RR
prevalence of novel risk factor
m
u
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Figure 1a 
Association between the prevalence of a novel risk factor and the multiplication factor. 
RR indicates relative risk of the novel risk factor.  
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Formula 2 provides the mathematical relationships between recalculated risk and 
prevalence of an ordinal novel risk factor for any level of relative risk (RR) and 
prevalence (P). 
 
Formula 2 
[r]    = p1*RR1 + p2*RR2 …….. + pn*RRn  
MFx = RRx/[r] 
Rx  =  Rbl*MFx  
 
[r] = weighted mean relative risk; p1 = prevalence of lowest level of risk; pn = prevalence of  
highest level of risk; RR1 = relative risk of lowest level of risk (= 1); RRn = relative risk of 
highest level of risk; x = xth level of risk; MFx = multiplication factor for patient with RRx; RRx = 
relative risk of xth level of risk; Rx = recalculated risk for patient with RRx; Rbl = baseline risk 
 
 
Derivation of formula 2 
Imagine a stratum with a baseline risk on a certain outcome. Within this stratum the novel risk factor is 
split into more than 2 possible levels, each with an accompanying RR. Baseline risk of the stratum is 
the sum of risks of all groups, each contributing with their specific weight. This weight is determined by 
the product of the prevalence (p) of each risk category and its accompanying RR. For the lowest level 
of risk, the accompanying RR is 1.0 by definition. The highest level of risk is noted as ‘n’.  The sum of 
all weights can be considered as a weighted mean of relative risks [r] , so: 
. 
Weighted mean RR = p1*RR1 + p2*RR2 …….. + pn*RRn = [r] 
 
The next step is to compare the RR of a specific level (RRx) of the novel risk factor to this ‘weighted 
mean RR’. This will give us a multiplication factor for baseline risk. 
MF(x) = RRx/[r]   
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Finally, to obtain recalculated risk, we have to multiply the baseline risk with this multiplication factor, 
so: recalculated risk for patient with level (ordinal) x = Rbl*MFx   
 
 
A graphic representation of how the multiplication factor depends on both relative risk and prevalence 
of different levels of an ordinal risk factor is shown in figure 2a. 
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Figure 2a. 
Association between weighted mean relative risk and multiplication factor for n levels of a risk 
factor. RR indicates relative risk of the novel risk factor.  
 
The mathematical problems with continuous risk factors  
Recalculation with a continuous risk factor is relatively easy if the relationship between exposure and 
risk is considered additive i.e. if the relation between the level of the risk factor and risk is represented 
by a straight line. The baseline risk then corresponds to the mean value of the risk factor, for example 
homocysteine (hcy), and the linear change in risk is simply the regression coefficient (ß). If the hcy-
level of a patient is n units different from the mean hcy, the recalculated risk will be: baseline risk + nß 
(formula 3). 
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Formula 3 provides the mathematical relationships between recalculated risk and mean 
value of a continuous risk factor for any value of the risk factor in a linear model. 
 
Formula 3 
Risk = (A –  )*ß  + Rbl 
A = value of the continuous risk factor in the patient;  = mean value of the risk factor in the 
stratum of the patient; ß = regression coefficients); Rbl = baseline risk 
 
Derivation of formula 3 
If risk changes linearly with every change of the continuous novel risk factor on the x-axis of 1 unit, 
then recalculation is carried out by measuring the distance on the x-axis between the level of the risk 
factor in the patient A and the mean level of this risk factor  .  
This difference, multiplied with the regression coefficient () shows the absolute difference in risk 
compared to baseline risk. If baseline risk is added, recalculated risk can be obtained.  
 
A graphic representation of the relationship between a continuous risk factor (hcy) and risk in an 
additive model is shown in figure 3.  
 
 
0 4 8 12 16 20 24
0.00
0.08
0.16
0.24
mean Hcy =   8 µmol/l
mean Hcy = 12 µmol/l
mean Hcy = 16 µmol/l
Hcy (µmol/l)
re
c
a
lc
u
la
te
d 
ris
k
β
 
 
 at GLASGOW UNIV LIB on November 18, 2011http://circ.ahajournals.org/Downloaded from 
 6 
 
Figure 3  Association between the level of homocysteine of the patient on the x-axis and 
recalculated risk, for 3 different levels of mean homocysteine in an additive model. Hcy 
indicates homocysteine level of the patient; ‘mean hcy’ indicates mean hcy for the stratum with 
a baseline risk of 0.08; ß indicates the regression coefficient (=0.008, i.e. if hcy increases 1 
mol/l, absolute risk changes 0.008)  
 
 
However, most continuous risk factors are presented in a multiplicative model, i.e. risk increases by a 
factor for a given change of the risk factor. The strength of the relation is usually expressed as a 
relative risk (RR) or odds ratio (OR). This type of relationship is not linear and can graphically be 
represented as a curve. In a non-linear model, the assumption that the mean value on the y-axis fits 
the mean value on the x-axis is incorrect. We explain this in figure 4. 
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Figure 4 Association between the level of homocysteine and recalculated risk in an 
multiplicative model for a stratum with a mean hcy of 14 umol/l and a baseline risk of 0.08 
(8%). Hcy indicates homocysteine.  
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Imagine the level of the continuous risk factor on the x-axis and risk on the y-axis. The baseline risk for 
our patient is 8%. Going in a straight line from this point to the right, one crosses the curve at a point 
with an accompanying value on the x-axis. Which point at the x-axis is it? In other words, if, for 
example homocysteine (hcy) is on the x-axis, which value of hcy fits the baseline risk of 8%? 
It is certainly not the mean value of this parameter, it must be lower. Let us imagine hcy to have a 
normal distribution, so there are as many values higher as there are lower values then mean-hcy. The 
higher values increase risk more than lower values will bring it down because of the multiplicative 
nature of the relationship. So the mean value of hcy correlates with a risk on the y-axis which is higher 
then 8%. In conclusion, the mean value on the x-axis (hcy), does not correspond to the mean value on 
the y-axis (=baseline risk)  
 
In fact, something very odd happens. Since the baseline risk of 8% corresponds to a hcy-value lower 
then the mean stratum-specific value of hcy, it follows that having the mean level of hcy is associated 
with a risk higher than 8%! So, in a multiplicative model, having the mean level of a (normally 
distributed) determinant increases risk above baseline risk. 
 
Theoretically, a mathematical formula could be constructed to calculate which hcy-value accompanies 
the baseline risk of 8%. However, things get increasingly difficult if the novel risk factor is not perfectly 
normally distributed, which will often be the case. In that case one would also need to account for 
skewness in the formula. 
 
For reasons mentioned above, we propose a pragmatic approach, which is to convert the continuous 
risk factor to risk categories which is discussed in the main text. 
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